AU2020357818A1 - Treatment of alcoholic hepatitis - Google Patents
Treatment of alcoholic hepatitis Download PDFInfo
- Publication number
- AU2020357818A1 AU2020357818A1 AU2020357818A AU2020357818A AU2020357818A1 AU 2020357818 A1 AU2020357818 A1 AU 2020357818A1 AU 2020357818 A AU2020357818 A AU 2020357818A AU 2020357818 A AU2020357818 A AU 2020357818A AU 2020357818 A1 AU2020357818 A1 AU 2020357818A1
- Authority
- AU
- Australia
- Prior art keywords
- 25hc3s
- salt
- subject
- dose
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908465P | 2019-09-30 | 2019-09-30 | |
| US62/908,465 | 2019-09-30 | ||
| US201962933206P | 2019-11-08 | 2019-11-08 | |
| US62/933,206 | 2019-11-08 | ||
| US202063060564P | 2020-08-03 | 2020-08-03 | |
| US63/060,564 | 2020-08-03 | ||
| US202063081208P | 2020-09-21 | 2020-09-21 | |
| US63/081,208 | 2020-09-21 | ||
| PCT/US2020/053315 WO2021067297A1 (en) | 2019-09-30 | 2020-09-29 | Treatment of alcoholic hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020357818A1 true AU2020357818A1 (en) | 2022-04-14 |
Family
ID=75336475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020357818A Pending AU2020357818A1 (en) | 2019-09-30 | 2020-09-29 | Treatment of alcoholic hepatitis |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220378802A1 (https=) |
| EP (1) | EP4037650A4 (https=) |
| JP (1) | JP7830313B2 (https=) |
| KR (1) | KR20220075329A (https=) |
| CN (2) | CN119868374A (https=) |
| AU (1) | AU2020357818A1 (https=) |
| BR (1) | BR112022005039A2 (https=) |
| CA (1) | CA3155422A1 (https=) |
| IL (1) | IL291287A (https=) |
| MX (1) | MX2022003778A (https=) |
| PH (1) | PH12022550698A1 (https=) |
| TW (1) | TW202128184A (https=) |
| WO (1) | WO2021067297A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3494125B1 (en) | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| EP4359420A4 (en) * | 2021-06-25 | 2025-07-16 | Durect Corp | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, PROCESSES FOR THEIR PREPARATION, AND THEIR USES |
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
| WO2025101669A1 (en) * | 2023-11-07 | 2025-05-15 | Durect Corporation | Treatment of alcohol-associated hepatitis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| US20150072962A1 (en) * | 2012-04-12 | 2015-03-12 | Virgini Commonwealth University | Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis |
| HRP20220112T1 (hr) * | 2013-12-24 | 2022-04-15 | Virginia Commonwealth University | Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre |
| EP3494125B1 (en) * | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| EP3493810A4 (en) * | 2016-08-02 | 2020-04-08 | Durect Corporation | COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE |
-
2020
- 2020-09-29 JP JP2022518230A patent/JP7830313B2/ja active Active
- 2020-09-29 CN CN202510090585.9A patent/CN119868374A/zh active Pending
- 2020-09-29 TW TW109133945A patent/TW202128184A/zh unknown
- 2020-09-29 AU AU2020357818A patent/AU2020357818A1/en active Pending
- 2020-09-29 WO PCT/US2020/053315 patent/WO2021067297A1/en not_active Ceased
- 2020-09-29 MX MX2022003778A patent/MX2022003778A/es unknown
- 2020-09-29 BR BR112022005039A patent/BR112022005039A2/pt unknown
- 2020-09-29 EP EP20871200.0A patent/EP4037650A4/en active Pending
- 2020-09-29 CA CA3155422A patent/CA3155422A1/en active Pending
- 2020-09-29 US US17/765,202 patent/US20220378802A1/en not_active Abandoned
- 2020-09-29 KR KR1020227010063A patent/KR20220075329A/ko active Pending
- 2020-09-29 CN CN202080068770.3A patent/CN114555044B/zh active Active
- 2020-09-29 PH PH1/2022/550698A patent/PH12022550698A1/en unknown
-
2022
- 2022-03-10 IL IL291287A patent/IL291287A/en unknown
-
2025
- 2025-10-21 US US19/364,999 patent/US20260102410A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7830313B2 (ja) | 2026-03-16 |
| TW202128184A (zh) | 2021-08-01 |
| CA3155422A1 (en) | 2021-04-08 |
| BR112022005039A2 (pt) | 2022-06-21 |
| US20220378802A1 (en) | 2022-12-01 |
| CN119868374A (zh) | 2025-04-25 |
| PH12022550698A1 (en) | 2023-04-03 |
| JP2022549621A (ja) | 2022-11-28 |
| CN114555044B (zh) | 2025-02-14 |
| CN114555044A (zh) | 2022-05-27 |
| EP4037650A4 (en) | 2023-10-18 |
| EP4037650A1 (en) | 2022-08-10 |
| MX2022003778A (es) | 2022-04-25 |
| IL291287A (en) | 2022-05-01 |
| WO2021067297A1 (en) | 2021-04-08 |
| KR20220075329A (ko) | 2022-06-08 |
| US20260102410A1 (en) | 2026-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260102410A1 (en) | Treatment of Alcoholic Hepatitis | |
| EP4185318B1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| US11970530B2 (en) | Methods of treating homologous recombination deficient cancer | |
| US20240024420A1 (en) | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | |
| JP2025041648A (ja) | 心血管有害事象のリスクのある対象における鉄欠乏症の処置 | |
| US20230372263A1 (en) | Methods and compositions for treating amyotrophic lateral sclerosis | |
| WO2021237146A1 (en) | Treatment of non-alcoholic steatohepatitis (nash) | |
| JP2022526914A5 (https=) | ||
| HK40073572B (zh) | 酒精性肝炎的治疗 | |
| HK40073572A (en) | Treatment of alcoholic hepatitis | |
| BR122025021620A2 (pt) | Composição compreendendo 25hc3s ou seu sal no tratamento de hepatite alcoólica | |
| WO2025101669A1 (en) | Treatment of alcohol-associated hepatitis | |
| AU2021273936A1 (en) | Treatment of non-alcoholic steatohepatitis (NASH) | |
| JP2022538210A (ja) | 腎機能障害患者における高アンモニア血症の治療 | |
| US20250025531A1 (en) | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | |
| WO2026026911A1 (zh) | 一种二肽衍生物的应用 | |
| HK40099476A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40094129B (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40094129A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40119109A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| WO2021237149A2 (en) | Treatment of non-alcoholic steatohepatitis (nash) | |
| Twisk et al. | Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 2 diabetes mellitus 3 |